Rate My Professor Mauro Perretti

Professor Mauro Perretti is Professor of Immunopharmacology at the William Harvey Research Institute, Queen Mary University of London, Faculty of Medicine and Dentistry. He received a Degree in Medicinal Chemistry in 1985 (110 cum laude) and a Certificate of Specialization in Pharmacology in 1988 (70 cum laude) from the University of Florence, Italy, and a PhD in 1996 from the University of London with a thesis entitled 'Lipocortin 1 and the control of neutrophil migration'. His professional career began at the Sclavo Research Centre in Siena, Italy (1987-1991), followed by joining the William Harvey Research Institute in 1991 as Research Scientist, advancing to Senior Scientist with Honorary Lecturer status (1993-1998), Senior Lecturer (1998-2000), Reader in Immunopharmacology (2000-2001), and Professor of Immunopharmacology since 2001. He has been Joint Head of the Centre for Biochemical Pharmacology since 2000, Deputy Director of the William Harvey Research Institute (2006-2013), Co-Director (2013-2016), and Dean for Research and Research Impact of the Faculty of Medicine and Dentistry (2015-2022). Perretti held Arthritis Research Campaign fellowships from 1997 to 2007.

Perretti's research interests center on the pathophysiology of inflammation, particularly the biology, mechanisms, and mediators of inflammation resolution, and the development of resolution pharmacology as a new therapeutic paradigm. He pioneered research in this field and collaborates with academic and commercial partners. His accolades include the Cattlin Prize in 1998 from the Joint Research Board of St. Bartholomew's Hospital, the Quintiles Prize in 2000 from the British Pharmacological Society for outstanding research in immunopharmacology, election as Fellow of the British Pharmacological Society in 2004, and Fellow of Academia Europaea in 2010. Among his key publications are 'Mobilisation of lipocortin 1 in adherent human polymorphonuclear leukocytes negatively modulates their transmigration' (Nature Medicine, 1996), 'Involvement of the receptor for formylated peptides (FPR) in the in vivo anti-migratory actions of annexin 1 and its mimetics' (American Journal of Pathology, 2001), and 'Exploiting the Annexin A1 pathway for the development of novel anti-inflammatory therapeutics' (British Journal of Pharmacology, 2009). With over 400 publications garnering more than 33,000 citations, his contributions have profoundly impacted immunopharmacology and inflammation research. He provides lectures on receptor theory, inflammatory models, and resolution of inflammation to students.